STEMCELLS INC Form 8-K July 18, 2011

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of)	Earliest Event Reported):	July 18, 2011
Dute of Iteport (Dute of	Zurnest Z vent reperteu).	vary 10, 2 011

StemCells, Inc.

(Exact name of registrant as specified in its charter)

Delaware	000-19871	94-3078125
(State or other jurisdiction of incorporation)	(Commission File Number)	(I.R.S. Employer Identification No
7707 Gateway Blvd, Suite 140, Newark, California		94560
(Address of principal executive offices)		(Zip Code)
Registrant s telephone number, including a	rea code:	650.456.4000
3	155 Porter Dr, Palo Alto, CA, 94304	
Former nam	e or former address, if changed since last	report

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

[Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Γ	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Edgar Filing: STEMCELLS INC - Form 8-K

Top	of	the	<u>e Form</u>	
				Events

On July 18, 2011, StemCells, Inc. (the "Company") announced the relocation of its corporate headquarters and U.S.-based research and development operations to 7707 Gateway Blvd, Newark, CA 94560.

The Company's press release announcing its corporate relocation is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incororated hereby by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit 99.1 Press Release of StemCells, Inc., dated July 18, 2011

Edgar Filing: STEMCELLS INC - Form 8-K

Top of the Form

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

StemCells, Inc.

July 18, 2011 By: /s/ Kenneth Stratton

Name: Kenneth Stratton Title: General Counsel

Edgar Filing: STEMCELLS INC - Form 8-K

Top of the Form

Exhibit Index

Exhibit No.	Description	
99.1	Press Release of StemCells, Inc., dated July 18, 2011	